Trials / Conditions / Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

27 registered clinical trials studyying Recurrent Nasopharyngeal Carcinoma — 11 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients NCT07247201	Singapore General Hospital	Phase 1 / Phase 2
Not Yet Recruiting	Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma NCT07088484	Fujian Cancer Hospital	—
Recruiting	Proton Therapy for Recurrent Nasopharyngeal Carcinoma NCT07412314	Guangzhou Concord Cancer Center	N/A
Recruiting	Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurre NCT06029270	National Cancer Institute (NCI)	Phase 2
Recruiting	Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC NCT06235203	Eye & ENT Hospital of Fudan University	Phase 3
Recruiting	Adjuvant vs Surgery Only in Early-stage Recurrent NPC NCT06228079	Eye & ENT Hospital of Fudan University	Phase 3
Recruiting	Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Me NCT05904080	National Cancer Institute (NCI)	Phase 2
Unknown	A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma NCT05432219	Eye & ENT Hospital of Fudan University	N/A
Recruiting	Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC NCT05350891	Eye & ENT Hospital of Fudan University	Phase 2
Unknown	Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma NCT05011227	Eye & ENT Hospital of Fudan University	Phase 2
Not Yet Recruiting	Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT NCT04215510	Eye & ENT Hospital of Fudan University	Phase 3
Terminated	Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Ci NCT04458909	National Cancer Institute (NCI)	Phase 3
Withdrawn	Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive NCT04231864	Alain Algazi	Phase 2
Unknown	A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma NCT04627961	National University Hospital, Singapore	Phase 2
Unknown	Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy NCT03689556	Shanghai Proton and Heavy Ion Center	—
Recruiting	Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma NCT04376866	Cancer Hospital of Guangxi Medical University	Phase 3
Unknown	Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for NCT04425265	Sun Yat-sen University	N/A
Unknown	Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. NCT04405622	Sun Yat-sen University	Phase 2
Unknown	Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failur NCT04586088	Sun Yat-sen University	Phase 2
Active Not Recruiting	Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carci NCT03930498	Sun Yat-sen University	Phase 2
Recruiting	PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients NCT03907826	Sun Yat-sen University	Phase 3
Unknown	Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma NCT04921995	Fudan University	Phase 2
Unknown	Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma NCT03639467	Chinese Academy of Medical Sciences	Phase 1 / Phase 2
Unknown	A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. NCT03210389	Sun Yat-sen University	Phase 2
Unknown	Nimotuzumab for Recurrent Nasopharyngeal Carcinoma NCT03666221	Fujian Cancer Hospital	Phase 2
Completed	Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) NCT01392235	Jiangsu HengRui Medicine Co., Ltd.	Phase 2
Completed	MK-2206 in Recurrent Nasopharyngeal Carcinoma NCT01370070	Chinese University of Hong Kong	Phase 2